Vir Biotechnology (VIR) Q2 2024 earnings summary

Executive summary

• Entered exclusive worldwide license agreement with Sanofi for three clinical-stage masked T-cell engagers and the Pro-XTEN protease-cleavable masking platform, enhancing the oncology and infectious disease pipeline; agreement subject to HSR clearance.

• Strategic restructuring includes a 25% workforce reduction (~140 employees), phasing out influenza, COVID-19, and viral vector programs, and prioritizing hepatitis delta, hepatitis B, and masked TCE assets.

• Pipeline now centers on hepatitis delta, hepatitis B, and the newly licensed T-cell engager portfolio, with multiple near-term clinical catalysts expected in the next 4–18 months.

• Focused capital allocation and cost savings expected to accelerate value inflection points and create a fit-for-purpose organization.

• Appointed new Chief Medical Officer and two new independent directors to strengthen leadership.

Financial highlights

• Q2 2024 total revenues were $3.1M, up from negative $13.8M in Q2 2023, driven by lower loss from sotrovimab sales and contract revenue.

• R&D expenses for Q2 2024 were $105.1M, down from $168.1M in Q2 2023, mainly due to lower clinical and manufacturing costs.

• SG&A expenses for Q2 2024 were $30.3M, down from $45.5M in Q2 2023, reflecting cost-saving initiatives.

• Net loss for Q2 2024 was $138.4M, improved from $194.8M in Q2 2023; net loss per share was $(1.02).

• Ended Q2 2024 with $1.43B in cash, cash equivalents, and investments.

Outlook and guidance

• 2024 GAAP operating expense guidance lowered by $70M to $580M–$610M, reflecting restructuring and program prioritization.

• Excludes $100M upfront and $75M milestone payments related to the Sanofi agreement, which will be incorporated in Q3 2024 guidance.

• Company expects $50M in annual workforce cost savings starting in 2025 and $50M in cost savings through end of 2025 from phased-out programs.

• Cash utilization in H2 2024 expected to be similar to H1 2024; existing cash and investments expected to fund operations for at least the next 12 months.

• Multiple value-driving clinical catalysts anticipated in the next 4–18 months, including hepatitis and T-cell engager programs.